US Merck Releases Phase 3 Study Findings of Keytruda Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Preliminary Data from BioPharmX Study Suggest Feasibility of BPX-01 1% and 2% in Patients with Rosacea

Aldeyra Therapeutics Reports Significant Improvement in Dry Eye Disease in Clinical Trial of Topical ADX-102 with Onset of Action Within One Week of Therapy

InDex Pharmaceuticals awarded Japanese patent for drug candidate cobitolimod

BioInvent to be granted patent by Japanese patent office for BI-1206

Manning Named to Palatin Technologies Board of Directors

Pulse Biosciences Withdraws 510(k) Application for the PulseTx System

ImmusanT Data Showing Increased Cytokine Levels after Gluten in Celiac Disease Provide Potential Basis for a Novel Diagnostic

FDA accepts BLA from Sandoz for proposed biosimilar rituximab

HanAll Biopharma and Harbour BioMed sign collaboration and licence agreement for development of therapies in Greater China

HanAll Biopharma signs strategic collaboration and license agreement with Harbour BioMed

Sandoz submits BLA with US FDA for proposed biosimilar for Rituxan (rituximab) to treat blood cancers

HanAll Biopharma partners with Harbour BioMed for two novel biologic therapies in Greater China

Ocular Therapeutix Names Goldstein as Chief Medical Officer

Ocular Therapeutix Names Goldstein as Chief Medical Officer